# Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

> **NCT05618613** · PHASE1,PHASE2 · TERMINATED · sponsor: **Context Therapeutics Inc.** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Elacestrant
- **DRUG:** Onapristone

## Key facts

- **NCT ID:** NCT05618613
- **Lead sponsor:** Context Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-02
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-06-23
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor decision to discontinue onapristone development.
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618613, "Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05618613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*